Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial (KGAD)
Generalized Anxiety Disorder
About this trial
This is an interventional treatment trial for Generalized Anxiety Disorder focused on measuring Kava, Anxiety, Generalized Anxiety Disorder, Psychiatric, Anxiolytic, GABA, Kavalactones
Eligibility Criteria
To be considered for inclusion in this study, participants will be required to meet the following criteria:
- Aged between 18-70 years
- Meets the Diagnostic and Statistical Manual (DSM) IV and DSM-V diagnostic criteria for generalised anxiety disorder (GAD) based on structured interview (Mini International Neuropsychiatric Interview-Plus 6 [MINI-Plus 6]. Note that while the MINI-Plus 6 uses the DSM-IV criteria, the same criteria are used in the DSM-V).
- Presents with anxiety (Hamilton Anxiety Rating Scale ≥ 18) at the time of study entry
- Fluent in written and spoken English
- Provides a signed copy of the consent form
Participants are ineligible to enter the trial if they have any of the following conditions:
- Primary diagnosis other than GAD
- Presentation of moderate to severe depressive symptoms (Montgomery-Asberg Rating Scale: MADRS ≥ 18 at time of study entry or ≥ 24 at any time during study)
- Presentation of suicidal ideation (≥ 3 on MADRS suicidal thoughts domain at time of study entry or at any time during study)
- Current diagnosis of bipolar disorder or schizophrenia on structured interview (MINI Plus)
- Current substance/alcohol use disorder on structured interview (MINI Plus) Page 21 of 39 Commercial-in-Confidence
- Currently taking an antidepressant, mood stabiliser, antipsychotic, anticonvulsant, warfarin or thyroxin, or current regular use (more than 2 days per week) of a benzodiazepine or opioid-based analgesic
- Current use of a psychotropic nutraceutical (e.g. St John's wort)
- Previous intolerance to kava
- Three or more failed trials of pharmacotherapy for the current GAD episode
- Recently commenced psychotherapy (within four weeks of study entry)
- Known or suspected clinically unstable systemic medical disorder
- Diagnosed hepato-biliary disease/inflammation
- Elevated liver enzymes at baseline blood test
- Pregnancy or breastfeeding, or trying to conceive
- Not using medically approved contraception (including abstinence) if female and of childbearing age
- Unable to participate in all scheduled visits, treatment plan, or other trial procedures according to the protocol (except for the optional genetic component)
Sites / Locations
- Royal Brisbane & Women's Hospital
- Centre for Human Psychopharmacology - Swinburne University
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Placebo
Kava - standardised 240mg kavalactones
Inert tablets matched for colour, size and consistency to active arm treatment. Both treatment arm tablets will match in appearance, and neither participants nor the trial clinicians will know what they are taking.
Standardised 240mg kavalactones per day - fixed dose regime of two tablets of kava twice per day